Iconoclast
Bluelighter
I have momentous news to share with you about our most recent accomplishment. On Friday, August 27, 2010, an official from the Drug Enforcement Administration (DEA) informed Dr. Michael Mithoefer that it had approved his Schedule 1 license for MAPS' MDMA/PTSD study in veterans with PTSD.
Obtaining the DEA's approval was our final regulatory requirement. The DEA has now joined the FDA and our Independent Review Board (IRB) by determining it is in the public interest for MAPS' study of MDMA-assisted psychotherapy in treating veterans of war to proceed.
The study will cost about $500,000 and take about two years, with most of the budget still to be raised. This study design is a prototype for our eventual Phase 3 multi-site studies.
Donations will enable MAPS to conduct essential research that will deepen and transform our healing partnership with all of our regulatory authorities, our veterans, and our society.
Triumphantly,
Rick
---
Rick Doblin, Ph.D.
MAPS Executive Director
Obtaining the DEA's approval was our final regulatory requirement. The DEA has now joined the FDA and our Independent Review Board (IRB) by determining it is in the public interest for MAPS' study of MDMA-assisted psychotherapy in treating veterans of war to proceed.
The study will cost about $500,000 and take about two years, with most of the budget still to be raised. This study design is a prototype for our eventual Phase 3 multi-site studies.
Donations will enable MAPS to conduct essential research that will deepen and transform our healing partnership with all of our regulatory authorities, our veterans, and our society.
Triumphantly,
Rick
---
Rick Doblin, Ph.D.
MAPS Executive Director

